Compare · CRBP vs NVO
CRBP vs NVO
Side-by-side comparison of Corbus Pharmaceuticals Holdings Inc. (CRBP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRBP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 2073.6x CRBP ($83.7M).
- Over the past year, CRBP is down 76.7% and NVO is down 28.6% - NVO leads by 48.1 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for CRBP).
- NVO has more recent analyst coverage (25 ratings vs 10 for CRBP).
- Company
- Corbus Pharmaceuticals Holdings Inc.
- Novo Nordisk A/S
- Price
- $4.50+4.04%
- $38.82-1.05%
- Market cap
- $83.7M
- $173.66B
- 1M return
- -38.03%
- -10.14%
- 1Y return
- -76.68%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 4
- Recent ratings
- 10
- 25
Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CRBP
- SEC Form 8-K filed by Corbus Pharmaceuticals Holdings Inc.
- SEC Form SCHEDULE 13G filed by Corbus Pharmaceuticals Holdings Inc.
- Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
- Director Ben Yong sold $15,683 worth of shares (2,000 units at $7.84) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 9,383 units (SEC Form 4)
- Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
- Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
- Chief Medical Officer Nicacio Leonardo Viana was granted 58,333 shares (SEC Form 4)
- Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Business Officer Saxena Nishant C bought $25,036 worth of shares (2,600 units at $9.63), increasing direct ownership by 3% to 77,900 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank